OCUL · Ocular Therapeutix, Inc · Investor Relations
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-10-20 13:45 UTC | Chardan 10th Annual Healthcare Conference | Conference |
Recent news
| Date | Headline |
|---|---|
| 2026-10-01 |
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026. |
| 2026-09-18 |
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to nine newly hired |
| 2026-09-15 |
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission for wet AMD remains on track for 4Q 2026 NDA submission to include subjects that |
| 2026-09-01 |
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October |
| 2026-08-13 |
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. |
| 2026-08-07 |
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired |
| 2026-08-03 |
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
Ocular’s AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence as Sufficient to Support Submission of AXPAXLI NDA in wet AMD AXPAXLI NDA submission to be |
| 2026-07-09 |
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eleven newly hired non-executive |
| 2026-07-01 |
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026. |
| 2026-06-22 |
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-15 | Baird 2026 Global Healthcare Conference | Conference |
| 2026-08-18 | Piper Sandler Virtual Fireside Chat | Event |
| 2026-07-22 | HC Wainwright 6th Annual Ophthalmology Virtual Conference | Conference |
| 2026-07-09 | Piper Sandler Virtual Ophthalmology Symposium | Event |
| 2026-06-17 | Ocular Therapeutix In-Person and Virtual Investor Day | Presentation |
| 2026-05-28 | Vanguards of Healthcare by Bloomberg Intelligence | Event |
| 2026-05-26 | Stifel 2026 Virtual Ophthalmology Forum | Event |
| 2026-05-12 | Bank of America Health Care Conference 2026 | Conference |
| 2026-05-05 | Ocular Therapeutix, Inc. Q1 Financial Results Conference Call | Earnings call |
| 2026-04-27 | HCW @ Home with Ocular Therapeutix | Event |
| 2026-04-13 | Vit-Buckle Society: SOL-1 Presentation Recap with Piper Sandler | Presentation |